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Abstract
Objective:  To  evaluate  treatment  adherence  among  perinatally-infected  pediatric  human
immunodeﬁciency virus  (HIV)  patients  followed  in  pediatric  centers  in  Brazil.
Methods: This  was  a  cross-sectional  multicenter  study.  Medical  records  were  reviewed  and
adherence  scale,  assessment  of  caregivers’  quality  of  life  (WHOQOL-BREF),  anxiety,  depres-
sion,  and  alcohol/substances  use/abuse  were  assessed.  Outcomes  included  self-reported  100%
adherence  in  the  last  three  days  and  HIV  viral  load  (VL)  <  50  copies/mL.  Statistical  analyses
included contingency  tables  and  respective  statistics,  and  multivariable  logistic  regression.
Results:  260  subjects  were  enrolled:  78%  children  and  22%  adolescents;  93%  of  caregivers  for
the  children  and  77%  of  adolescents  reported  100%  adherence;  57%  of  children  and  49%  of
adolescents  had  VL  <  50  copies/mL.  In  the  univariate  analyses,  HIV  diagnosis  for  screening  due
to  maternal  infection,  lower  caregiver  scores  for  anxiety,  and  higher  scores  in  physical  and
psychological  domains  of  WHOQOL-BREF  were  associated  with  100%  adherence.  Shorter  inter-
vals  between  pharmacy  visits  were  associated  with  VL  <  50  copies/mL  (p  ≤  0.01).  Multivariable
regression  demonstrated  that  caregivers  who  did  not  abuse  alcohol/other  drugs  (OR  =  0.49;  95%
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CI:  0.27-0.89)  and  median  interval  between  pharmacy  visits  <  33  days  (OR  =  0.97;  95%  CI:  0.95-
0.98)  were  independently  associated  with  VL  <  50  copies/mL;  whereas  lower  caregiver  scores  for
anxiety  (OR  =  2.57;  95%  CI:  1.27-5.19)  and  children’s  HIV  diagnosis  for  screening  due  to  maternal
infection  (OR  =  2.25;  95%  CI:  1.12-4.50)  were  found  to  be  independently  associated  with  100%
adherence.
Conclusions:  Pediatric  HIV  programs  should  perform  routine  assessment  of  caregivers’  quality
of life,  and  anxiety  and  depression  symptoms.  In  this  setting,  pharmacy  records  are  essential
to  help  identify  less-than-optimal  adherence.
©  2014  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  
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Supressão  viral  e  adesão  entre  crianc¸as  e  adolescentes  vivendo  com  HIV  na  terapia
antirretroviral:  resultados  de  um  estudo  multicêntrico
Resumo
Objetivo:  Avaliar  a  adesão  ao  tratamento  antirretroviral  entre  portadores  de  HIV  acompanhados
em centros  pediátricos.
Métodos: Trata-se  de  estudo  transversal  multicêntrico.  Os  prontuários  ambulatoriais  foram
revistos e  aplicadas  escala  de  adesão,  avaliac¸ão  de  qualidade  de  vida  (WHOQOL-BREF),
ansiedade, depressão  e  uso  indevido  de  álcool/substâncias  entre  cuidadores.  Os  desfechos
incluíram  autorrelato  100%  de  adesão  nos  últimos  três  dias  e  carga  viral  do  HIV  (CV)  <  50
cópias/mL.
Resultados:  260  indivíduos  foram  incluídos,  79%  crianc¸as  e  21%  adolescentes;  93%  das  crianc¸as
e 77%  dos  adolescentes  relataram  100%  de  adesão;  57%  das  crianc¸as  e  49%  dos  adolescentes
tinham CV  <  50  cópias  /mL.  Na  análise  univariada,  diagnóstico  do  HIV  por  triagem  devido  à
infecc¸ão  materna,  cuidador  com  pontuac¸ão  menor  para  ansiedade  e  maior  nos  domínios  físico
e  psicológico  do  WHOQOL-BREF  se  mostraram  independentemente  associados  a  100%  de  adesão.
Intervalos  mais  curtos  entre  visitas  de  farmácia  foram  associados  com  CV  <  50  cópias  /mL  (p  ≤
0,01).  Regressão  multivariada  mostrou  que  os  cuidadores  sem  abuso  de  álcool/outras  drogas
(OR  =  0,49;  IC95%  0,27-0,89)  e  o  intervalo  médio  entre  visitas  de  farmácia  <  33  dias  (OR  =  0,97;
IC95%  0,95-0,98)  foram  associados  com  CV  <  50  cópias/mL;  cuidador  com  menores  escores  para
ansiedade  (OR  =  2,57;  IC95%  1,27-5,19)  e  diagnóstico  de  crianc¸as  por  triagem  devido  à  infecc¸ão
materna (OR  =  2,25;  IC95%  1,12-4,50)  foram  associados  com  100%  de  adesão.
Conclusões:  Programas  de  HIV  pediátrico  devem  avaliar  qualidade  de  vida  e  sintomas  de
ansiedade e  depressão  dos  cuidadores.  Registros  de  farmácia  são  essenciais  na  identiﬁcac¸ão
de adesão  insatisfatória.
© 2014  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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n  Brazil,  13,758  cases  of  perinatally-acquired  human
mmunodeﬁciency virus  (HIV)  infection  were  reported  as
f July  2013.1 Access  to  combined  antiretroviral  ther-
py (cART)  has  changed  the  course  of  HIV  disease  among
razilian perinatally-infected  children.2 Sustained  adher-
nce to  therapy  is  the  most  important  determinant  of
uccessful treatment  and  is  especially  challenging  among
IV-infected children  and  adolescents  due  to  reasons  such
s dependency  on  caregivers,  attitudes  of  deﬁance/denial,
nd delay  in  diagnosis  disclosure  to  children.3--5 This  study’s
im was  to  evaluate  treatment  adherence  among  peri-
atally HIV-infected  children  and  adolescents  based  on biomedical  (viral  suppression)  and  a  behavioral  (cART
issed doses)  outcome,  and  to  explore  possible  barriers
o satisfactory  adherence  among  the  Brazilian  popula-
ion.
l
s
cethods
his  was  a  cross-sectional  study  conducted  in  ﬁve  Brazilian
enters, each  located  in  one  of  the  ﬁve  Brazilian  macro-
egions.
Perinatally HIV-infected  children  and  adolescents  (0  to
8 years)  on  cART  for  at  least  eight  weeks  were  eligi-
le. Retrievable  laboratory  evaluations  within  six  months
f the  study’s  inception  were  recorded.  Study  participa-
ion was  offered  as  patients  attended  regular  clinic  visits
ith their  legal  guardians.  Study  centers  have  routine  adher-
nce support  initiatives  that  include  individual  and  familiar
ounseling and  group  activities;  these  strategies  were  not
odiﬁed during  study  enrollment.
After  signing  the  informed  consent,  caregivers  and  ado-
escents answered  structured  questionnaires  that  included
ociodemographic information,  number  of  missed  doses  of
ART in  the  last  three  days,  and  the  short  version  of  the
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was seven  years  (SD  =  3.7).  Forty-ﬁve  (17%)  children  had
used mono-  or  dual  therapy  before  starting  cART.  At  enroll-
ment, 61%  of  children/adolescents  were  using  cART  with
protease inhibitors  (PI)  and  39%  were  using  cART  with  a  non-Treatment  adherence  among  HIV-infected  children  
World  Health  Organization  (WHO)  questionnaire  for  qual-
ity of  life  (WHOQOL-BREF).6 Adherence  assessment  was
peformed by  trained  healthcare  workers  with  caregivers
whenever the  patient  was  a  child  (<  13  years),  and  directly
with adolescents.
All caregivers  answered  the  Alcohol,  Smoking,  and  Sub-
stance Involvement  Screening  Test  (ASSIST).7 Anxiety  and
depression were  assessed  among  caregivers  and  adoles-
cents using  the  Hospital  Anxiety  and  Depression  Scale
(HADS).8 Medical  records  were  reviewed  aiming  to  col-
lect data,  including:  acquired  immunodeﬁciency  syndrome
(AIDS) deﬁning  diagnosis,  previous  hospitalizations,  CD4  +  T
lymphocyte cell  counts,  HIV  viral  load,  and  information
about the  reason  for  initial  HIV  test  (symptomatic  children
vs. HIV-exposed  children  screened  in  the  context  of  family
screening). Pharmacy  records  were  electronically  available
at every  clinical  center  and  routine  dispensing  was  sched-
uled to  occur  on  a  monthly  basis.
Sample  size  was  calculated  based  on  the  clientele  reg-
istered for  follow-up  and  treatment  at  participating  sites,
considering results  of  a  previous  study  in  Brazil  on  adher-
ence among  children  and  adolescents,9 a  statistical  power
of 80%,  and  an  alpha  error  of  5%.  Outcomes  for  optimal
adherence were  deﬁned  as  no  missed  doses  of  cART  in  the
last three  days  (100%  adherence)  and  viral  load  below  the
limit of  detection  (<  50  copies/mL)  in  the  exam  closest  to
enrollment.
Data were  stored  and  analyzed  using  SPSS  18.0  software
(SPSS Statistics  for  Windows,  Version  18.0.  Chicago,  USA).
The level  of  signiﬁcance  adopted  in  uni-  and  multivariable
logistic regression  analyses  was  0.05.  Contingency  tables
and respective  statistics  were  used  to  assess  the  putative
association between  predictor  variables  (e.g.,  sociodemo-
graphic, biological  [extracted  from  patients’  case  report
charts], QOL  scores,  anxiety  and  depression  scores,  alcohol
and substance  use  and  abuse)  and  the  two  outcomes:  cART
adherence and  viral  suppression.  Multiple  logistic  regres-
sion was  used  to  assess  factors  that  showed  association  with
the outcomes  with  p-values  <  0.25  in  the  univariate  analy-
ses and  to  investigate  independent  predictors  by  controlling
for possible  confounders.  Models  ﬁtness  was  veriﬁed  by
Hosmer-Lemeshow statistics  and  analysis  of  residuals  (data
not shown).
The research  protocol  was  submitted  and  approved  by
the institutional  review  board  of  each  site:  Hospital  dos
Servidores do  Estado  do  Rio  de  Janeiro  (Rio  de  Janeiro,
RJ, Brazil),  Fundac¸ão  de  Medicina  Tropical  do  Amazonas
(Manaus, AM,  Brazil),  Instituto  de  Medicina  Integral  Prof.
Fernando Figueira  (Recife,  PE,  Brazil),  Grupo  Hospitalar
Conceic¸ão (Porto  Alegre,  RS,  Brazil),  and  Universidade  Fed-
eral de  Mato  Grosso  do  Sul  (Campo  Grande,  MS,  Brazil).
Results
From  December  of  2009  to  April  of  2011,  572  HIV-infected
children (<  13  years)  and  adolescents  (>  13  and  <  18  years)
attended HIV  clinics  at  the  ﬁve  participating  sites.  From  this
total, 60  were  not  using  cART  or  had  been  using  it  for  less
than eight  weeks;  24  were  infected  by  means  other  than
vertical transmission;  19  did  not  have  a  legal  guardian;  74
consented but  did  not  complete  the  study  procedures;  48
n
r
(
t565
id  not  agree  to  participate;  and  87  were  not  invited  due
o conﬂicting  schedules.  Therefore,  260  pairs  of  perinatally
IV-infected children  or  adolescents  and  their  respective
aregivers were  enrolled  into  the  study  and  completed
he study  procedures.  Sociodemographic  characteristics  of
nrolled patients  were  similar  to  those  of  the  whole  group.
owever, viral  suppression  among  patients  on  cART  was
igniﬁcantly worse  among  the  whole  group  (51%),  when  com-
ared  to  those  fully  enrolled  (58%)  (p  <  0.01).  The  study
opulation comprised  203  children  (78%)  and  57  adolescents
22%).
IV  testing  and  diagnosis
08/260  (42%)  of  the  patients  had  HIV  testing  and  diag-
osis elicited  by  a  symptomatic/clinical  condition  (not
ecessarily an  AIDS-deﬁning  condition);  76/260  (29%)  were
ested  because  someone  else  in  the  family  had  HIV
i.e., family  screening),  and  73/260  (28%)  were  found
o be  HIV-infected  in  the  ﬁrst  months  of  life,  during
ollow-up as  an  infant  born  to  an  HIV-infected  mother.
nformation could  not  be  obtained  for  three  asymptomatic
hildren. Due  to  these  distinct  situations  that  inﬂuenced
he timing  of  HIV  diagnosis,  children  began  to  attend
he clinic  at  mean  ages  of  4.5  years  (SD  =  4.1),  4.3  years
SD =  3.5),  and  0.8  years  (SD  =  1.8),  respectively.  Children
ssessed for  AIDS-related  symptoms  were  compared  vis-à-
is the  other  two  groups  (i.e.  those  enrolled  after  family
creening or  routine  follow-up  of  infants  born  to  an  HIV-
nfected mother).  Mean  age  at  study  entry  was  9.2  years
SD =  4.3).
enters  for  Disease  Control  and  Prevention  (CDC)
994 Classiﬁcation10
t  the  time  of  referral  to  HIV  specialized  care  centers,
0/260 subjects  were  classiﬁed  as  CDC  clinical  category  N
34.6%); 27/260,  as  clinical  category  A  (10.4%);  73/260,  as
linical category  B  (28.1%);  and  68/260,  as  clinical  cate-
ory C  (26.2%).  Information  could  not  be  obtained  for  two
hildren. 83/260  (31.9%)  already  had  advanced  immunode-
ciency (CDC  3  immune  category).  Thus,  116/260  (44.6%)  of
hildren/adolescents had  already  progressed  to  AIDS  when
rst admitted  to  care  (CDC  categories  C  and/or  3),  and  35
13.4%) of  them  were  classiﬁed  as  C3.
ART  use
t  the  time  of  study  enrollment,  the  mean  duration  of  cARTucleoside reverse  transcriptase  inhibitor  (NNRTI)-based
egimen; 98/260  (37.7%)  were  on  their  ﬁrst  regimen,  62/260
23.8%) on  their  second  regimen,  and  100/260  (38.5%)  on
heir third  regimen  or  beyond.
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dherence  assessment
88/203  (92.6%)  of  the  children  (caregivers’  information)
nd 44/57  (77.2%)  of  the  adolescents  reported  no  missed
oses of  cART  in  the  last  three  days  (100%  adherence).
iral  suppression
20/203  (57%)  of  children  and  28/57  (49%)  of  adolescents
ad plasma  viral  loads  bellow  50  copies/mL  at  the  clinical
isit closest  to  enrollment.  The  chance  of  viral  suppression
id not  differ  among  those  who  had  received  mono-  or  dual
herapy prior  to  cART  initiation  (OR  =  1.0;  95%  CI:  0.70  --  1.5).
ssociation  between  optimal  adherence  and  viral
uppression
he  two  proposed  outcomes  (viral  load  <  50  copies/mL  and
o ART  missed  dose  in  the  last  three  days)  had  no  statistical
ssociation (p  =  0.34)  for  both  children  and  adolescents.
aregiver  parameters
ver  half  of  the  caregivers  (142/260;  54.6%)  were  HIV-
nfected (mostly  a  biological  parent),  102/260  (39.2%)  were
ot  infected  by  HIV  (‘‘uninfected’’),  and  16/260  (6.2%)
id not  know  their  HIV  status.  Caregivers  living  or  not
iving with  HIV  had  similar  sociodemographic  characteris-
ics, except  that  HIV-infected  caregivers  were  signiﬁcantly
ounger, compared  to  those  who  were  not  living  with  HIV
p < 0.01),  as  shown  in  Table  1.  HIV-infected  caregivers  were
ore likely  to  abuse  alcohol  or  other  substances  than  unin-
ected caregivers  (p  =  0.02).
harmacy  records
52/260  patients  (97%)  had  available  pharmacy  records.
edian interval  between  pharmacy  visits  for  cART  reﬁll  in
he last  twelve  months  was  32  days  for  children  who  showed
iral suppression  and  40  days  for  those  with  detectable  viral
oad (prevalence  ratio  [PR]  =  1.65  [95%  CI:  1.32-2.40]).
nivariate  analysis
able  2  shows  the  distribution  of  key  covariates  from  chil-
ren/adolescents and  their  putative  associations  with  the
wo outcomes  under  analysis.  Table  3  summarizes  ﬁndings
n caregivers’  anxiety  and  depression  assessment,  screening
or alcohol  and  other  substance  abuse,  and  scores  related
o quality  of  life  and  their  putative  association  with  the  two
utcomes among  children/adolescents.
ultivariable  analyses
linically  relevant  covariates  associated  with  the  outcomes
t the  level  of  p  <  0.25  in  the  univariate  analyses  were
ncluded in  the  model.  All  intermediary  steps  and  the  ﬁnal
odel were  controlled  for  age.  Multivariable  logistic  regres-
ion showed  that  caregivers  who  did  not  abuse  alcohol  and
s
A
o
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ther  drugs  (OR  =  0.49;  95%  CI:  0.27-0.89),  as  well  as  those
ho came  to  the  pharmacy  for  cART  reﬁll  with  median  inter-
al less  than  33  days  (OR  =  0.97;  95%  CI:  0.95-0.98)  were
ndependently associated  with  viral  load  <  50  copies/mL
mong children  and  adolescents;  whereas  caregivers  with
nxiety score  less  than  8  at  HAD  (OR  =  2.57;  95%  CI:  1.27-
.19) and  children  who  had  HIV  diagnosis  as  a  result  of  family
creening (OR  =  2.25;  95%  CI:  1.12-4.50)  were  found  to  be
ndependently associated  with  no  missed  doses  of  ART  in
he last  three  days.
iscussion
t  study  admission,  over  half  (59%)  of  the  children  and  half
f the  adolescents  had  viral  suppression,  whereas  roughly
3% of  children  and  77%  of  adolescents  reported  no  missed
oses of  ART  in  the  last  three  days,  which  suggests  both
aregivers for  the  children  and  adolescents  tended  to  over-
stimate their  actual  adherence.  It  is  very  unlikely  that  such
ronounced discrepancies  between  self-reported  adherence
nd viral  load  is,  above  all,  due  to  secondary  to  errors
n prescription  and/or  the  emergence  of  drug  resistance
ver short  periods  of  time.  The  study  was  performed  in
eferral centers,  where  patients  were  managed  by  experi-
nced physicians  and  multidisciplinary  health  teams,  with
ull access  to  a  comprehensive  portfolio  of  ARV  medicines,
t no  cost  at  the  point  of  delivery.
The  present  results  were  comparable  to  other  recent
razilian studies.11,12 Filho  et  al.  interviewed  101  adoles-
ents in  Rio  de  Janeiro  regarding  missed  doses  of  cART  in
he last  three  days  and  observed  that  80%  were  adherent
o treatment.  Ernesto  et  al.  studied  108  children  and  ado-
escents in  Campinas,  and  interviewed  them  regarding  the
se of  cART  in  the  last  24  h  and  the  last  seven  days,  as
ell as  checked  their  pharmacy  records.  The  authors  found
hat 54.6%  of  the  study  population  could  be  deﬁned  as  non-
dherent, considering  at  least  one  of  these  outcomes.
There  is  no  gold  standard  with  respect  to  the  proper
easurement of  adherence,  for  either  adults  or  chil-
ren/adolescents. Questionnaires  about  missed  doses  of
ART are  frequently  used  to  evaluate  adherence  in  pediatric
opulations.9,13--18 Other  commonly  used  methods  include
ill counts,  records  of  pharmacy  visits,  medication  diaries,
lectronic devices  such  as  Medication  Event  Monitoring  Sys-
em  (MEMS)  (MWV  Healthcare,  Sion,  Switzerland)  caps,
nd therapeutic  drug  monitoring.  A  systematic  literature
eview on  adherence  evaluation,  which  included  176  stud-
es, demonstrated  the  use  of  a  single  method  in  most  studies;
n 71%,  self-administered  questionnaires  were  the  method  of
hoice.19
Many  studies  involving  HIV-infected  patients  using  of
ART have  found  good  association  between  viral  suppres-
ion and  adherence  scale  scores,  including  validated  scales
ssessing self-reported  missed  doses.14,15,20,21 However,  the
resent results  corroborate  those  of  Mellins  et  al.15 and  Alli-
on et  al.,21 presenting  ﬁndings  from  studies  conducted  in
he United  States.  These  two  studies  did  not  demonstrate
igniﬁcant associations  between  reported  missed  doses  of
RT in  the  last  days  and  viral  suppression.  A  meta-analysis
n the  association  between  adherence  to  cART  and  viral
uppression among  children,  adolescents,  and  young  adults
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Table  1  Sociodemographic  characteristics  of  caregivers  according  to  HIV  status.
N  HIV  +  caregivers  HIV-/unknown  caregivers  p
n  (%)  n  (%)
Caregiver  gender
Male 18  8  (44.4%)  10  (55.6%)  0.33
Female  242  136  (56.2%)  106  (43.8%)
Religious
Yes 215 117  (54.4%)  98  (45.6%)
No  45  27  (60%)  18  (40%)  0.49
Presently  employed?
Yes 109  64  (58.7%)  45  (41.3%)
No  151  80  (53%)  71  (47%)  0.36
Total  schooling  years
< 8  years 130  70  (53.8%)  60  (46.2%)  0.66
≥  8  years 129 73  (56.6%)  56  (43.4%)
Marital  status
Single/separated/divorced/widow/other  relationship  118  74  (62.7%)  44  (37.3%)  0.22
Married/stable  union  112  60  (49.2%)  62  (50.8%)
HIV, human immunodeﬁciency virus; HIV + , caregiver living with HIV; HIV-/unknown, caregiver not living with HIV or with unknown status
for HIV.
Table  2  Univariate  analysis  of  sociodemographic  and  clinical  data  of  children/adolescents  and  their  association  with  proposed
outcomes  (viral  load  <  50  copies/mL  and  100%  adherence).
Variable N  Viral  load  <  50  copies/mL 100%  adherence
Yes  No  PR  (95%  CI)  Yes  No  PR  (95%  CI)
Gender
Male  133  73  (54.9%)  60  (45.1%)  1.10  (0.83-1.46)  105  (78.9%)  28  (21.1%)  1.22  (0.74-2.00)
Female  127  75  (59.1%)  52  (40.1%)  105  (82.7%)  22  (17.3%)
Condition of  child’s  HIV  diagnosis
Family screening  152  89  (58.6%)  63  (41.4%)  130  (85.5%)  22  (14.5%)
Symptomatic 108  59  (54.6%)  49  (45.4%)  1.10  (0.83-1.45)  80  (74.1%)  28  (25.9%)  1.79  (1.09-2.96)
CDC  1994  at  admission
Non-AIDS 116  87  (60.4%)  57  (39.6%)  116  (80.6%)  28  (19.4%)
AIDS 144  61  (52.9%)  55  (47.4%)  1.20  (0.91-1.58)  94  (81.0%)  22  (19.0%)  0.98  (0.59-1.61)
Present  cART
With NNRTI  100  62  (62.0%)  38  (38.0%)  81  (81.0%)  19.0  (19.0%)
With PI  160  86  (53.8%)  74  (46.3%)  1.22  (0.90-1.65)  129  (80.6%)  31  (19.4%)  1.02  (0.61-1.70)
Number  of  ART  regimens
1 98  60  (61.2%)  38  (38.8%)  82  (83.7%)  16  (16.3%)
≥ 2  162  88  (54.3%)  74  (45.7%)  1.18  (0.87-1.59)  128  (79.0%)  34  (21.0%)  1.29  (0.75-2.20)
Caregiver  HIV  status
HIV- /  unknown  118  67  (56.8%)  51  (43.2%)  99  (83.9%)  19  (16.1%)
HIV +  142  81  (57.0%)  61  (43.0%)  0.99  (0.75-1.32)  111  (78.2%)  31  (21.8%)  1.36  (0.81-2.28)
Days  between  pharmacy  visits  for  ART  reﬁll  (median)
≤  33  77  54  (70.1%)  23  (29.9%)  63  (81.8%)  14  (18.2%)
> 33  175  89  (50.9%)  86  (49.1%)  1.65  (1.32-2.40)  140  (80.0%)  35  (20.0%)  1.10  (0.63-1.92)
PR, prevalence ratio; CI, conﬁdence interval; HIV, human immunodeﬁciency virus; CDC, Centers for Disease Control and Prevention; HIV + ,
caregiver living with HIV; HIV-/unknown, caregiver not living with HIV or with status unknown for HIV; cART, combined antiretroviral
therapy; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; ART, antiretroviral therapy.
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Table  3  Results  of  caregivers’  evaluations  of  anxiety  and  depression,  screening  for  misuse  of  alcohol  and  other  substances  (ASSIST  scores  ≥  cut-off)  and  quality  of  life
(WHOQOL-BREF with  its  domains)  and  their  association  with  studies  outcomes  children/adolescents.
N  Children/adolescents  with  VL  <  50  copies/mL  PR  (95%  CI)a Children/adolescents  with  100%  adherence  PR  (95%  CI)
Yes  %  No  %  Yes  %  No  %
Caregiver  gender
Male 18  13  (72.2%)  5  (27.8%)  194  (80.2%)  48  (19.8%)
Female 242  135  (55.8%)  107  (44.2%)  0.63  (0.29-1.34)  16  (88.9%)  2  (11.1%)  0.56  (0.15-2.12)
Anxiety
Score ≥  8  113  77  (56.2%)  60  (43.8%)  119  (86.9%)  18  (13.1%)
Score <  8  137  63  (55.8%)  50  (44.2%)  1.01  (0.76-1.34)  84  (74.3%)  29  (25.7%)  1.95  (1.15-3.33)
Depression
Score ≥  9  95  88  (56.8%)  67  (43.2%)  130  (83.9%)  25  (16.1%)
Score <  9  155  52  (54.7%)  43  (45.3%)  1.05  (0.79-1.39)  73  (76.8%)  22  (23.2%)  1.44  (0.86-2.40)
Abuse of  alcohol/other  substance
Yes  89  102  (60.4%)  67  (39.6%)  141  (83.4%)  28  (16.6%)
No 169  44  (49.4%)  45  (50.6%)  1.28  (0.97-1.68)  67  (75.3%)  22  (24.7%)  1.49  (0.90-2.45)
Quality  of  life  (Domains)b Mean  rank  Mean  rank  Mann-Whitney  U  Mean  rank  Mean  rank  Mann-Whitney  U
Physical  109  27.13  139  27.53  0.52  46  26.26  202  27.61  0.04
Psychological 109  21.8  141  22.26  0.38  47  20.69  203  22.37  0.00
Social 101  10.28  129  10.79  0.22  44  10.02  186  10.69  0.18
Environmental/contextual  108  23.91  141  25.14  0.09  46  23.76  203  24.8  0.17
ASSIST, Alcohol, Smoking and Substance Involvement Screening Test; WHOQOL-BREF, short version of the WHO questionnaire for quality of life; VL, viral load; PR, prevalence ratio; CI,
conﬁdence interval.
a Contingency tables and respective statistics.
b As assessed by Mann-Whitney.
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(Treatment  adherence  among  HIV-infected  children  
found  that  this  relationship  was  stronger  for  longitudinal
studies when  compared  to  cross-sectional  studies,  and  that
this association  tended  to  be  weaker  (or  absent)  when  the
informant was  the  caregiver.22
In  the  present  study,  ‘‘no  missed  cART  doses  in  the  last
three days’’,  as  reported  by  patients/caregivers,  was  found
to be  associated  with  improved  quality  of  life  of  caregivers,
low anxiety  scores,  as  well  as  the  context  and  timing  of
HIV diagnosis,  with  better  adherence  found  among  those
diagnosed by  family  screening.  Most  of  these  ﬁndings  are  in
accordance with  previous  pediatric  studies.  In  2004,  Mellins
et al.  interviewed  75  caregivers  in  the  United  States  about
their children’s  ART  missed  doses  in  the  last  month  and
observed that  non-adherence  was  associated  with  worse
parent-child communication,  higher  levels  of  stress,  and
lower quality  of  life  among  caregivers,  as  well  as  poor  cogni-
tive functioning  and  less  open  disclosure  of  caregivers’  HIV
status to  others.15 A  systematic  review  on  adherence  to  cART
versus quality  of  life  among  adults  living  with  HIV  identiﬁed
12 studies,  most  of  them  aiming  to  evaluate  how  adher-
ence has  been  associated  with  quality  of  life  as  a  treatment
outcome.23 Different  results  suggest  that  a  virtuous  cycle
may exist,  with  optimal  adherence  and  a  high  quality  of  life
boosting each  other  through  a  feedback  loop.  Anxiety  has
been previously  identiﬁed  as  a  predictor  of  non-adherence
among HIV-infected  adults.  A  comprehensive  survey  imple-
mented in  the  United  States  on  behalf  of  the  HIV  Cost  and
Services Utilization  Study  found  anxiety  disorder,  depres-
sion, and  drug  use  as  key  risk  factors  for  non-adherence.24
Findings  from  a  Brazilian  study  conducted  in  adults  using
the same  instrument  as  that  of  the  present  study  (Hospital
Anxiety and  Depression  Scale)  were  similar  to  these  results.
In this  previous  study,  high  scores  for  anxiety  were  found
to be  associated  with  an  increased  risk  of  non-adherence,
whereas no  association  was  found  with  depression  scores.25
Caregivers  of  children  and  adolescents  who  were
diagnosed in  the  context  of  routine  screening  of  perinatally-
exposed children  were  more  likely  to  report  no  missed  cART
dose in  the  last  three  days  when  compared  to  those  whose
HIV testing  had  been  motivated  by  clinical  events/symptoms
(not necessarily  an  AIDS-deﬁning  illness).  The  present  ﬁnd-
ings differ  from  those  shown  by  PENTA  5,  where  sicker
children had  better  adherence  to  treatment.14 The  present
data suggest  that  families  who  accept  screening  procedures
for children  whenever  a  parent  or  sibling  has  a  diagnosis
of HIV  infection  may  be  more  likely  to  adhere  to  treatment.
The WHO  estimates  that  only  15%  of  HIV-exposed  infants  are
tested in  the  ﬁrst  months  of  life  in  low-  and  middle-income
countries. In  Brazil,  many  programs  devoted  to  prevention  of
mother-to-child-transmission of  HIV  (PMTCT)  seek  to  stim-
ulate the  full  integration  of  maternal  and  pediatric  care,
and offer  continued  family  follow-up,  which  is  the  case  of
the ﬁve  participating  sites  in  this  study.  This  study’s  results
reinforce the  importance  of  this  familiar  approach,  which
enables the  early  diagnosis  of  infected  children  and  may
contribute to  improved  adherence.
These  ﬁndings  on  viral  suppression  are  similar  to  previ-
ous studies  carried  out  in  the  present  cART  era.  A  previous
Brazilian study,  in  Campinas,  SP,  found  that  50%  of  children
and adolescents  had  a  viral  load  <  50  copies/mL  in  their  last
exam.12 A  recent  study  among  65  HIV-infected  children  in
Gambia found  that  58%  had  viral  suppression  after  36  months
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f  cART  initiation;  in  Kenya,  47%  and  67%  of  43  children
chieved viral  suppression  to  less  than  100  copies/mL  and
00 copies/mL,  respectively,  after  six  months  of  cART.  In
 United  States-based  study,  among  126  children  aged  3-13
ears using  cART  for  an  average  of  2.6  years,  36%  achieved
iral suppression.  Among  437  children  from  13  European
ountries, 53%  achieved  viral  suppression  at  12  months  of
reatment. In  the  present  study,  no  signiﬁcant  differences
ere found  with  respect  toviral  suppression  in  children  and
dolescents previously  exposed  to  mono-  or  dual  therapy,
ompared with  those  whose  ﬁrst  regimen  was  cART.  This
nding is  in  accordance  with  the  observation  that  starting
reatment with  mono-  or  dual  therapy  did  not  have  sig-
iﬁcant impact  on  survival  among  children  transitioning  to
ART.26
The  independent  association  of  alcohol  and  drug  abuse
mong caregivers  as  measured  by  ASSIST7 and  viral  sup-
ression among  children  indicates  the  usefulness  of  this
nstrument in  pediatric  HIV  clinics.  This  ﬁnding  is  not  surpris-
ng, since  alcohol  use  among  HIV-infected  adults  has  been
ssociated with  lower  treatment  adherence,  incomplete
iral suppression,  and  disease  progression.  In  a  systematic
eview of  the  literature,  a  negative  association  of  moder-
te/heavy alcohol  consumption  and  viral  suppression  was
ade evident.27 The  incorporation  of  a  screening  instrument
or drug  use  among  caregivers  may  contribute  to  strategies
iming to  improve  adherence  in  the  pediatric  population,
ince among  HIV-infected  adults,  the  proper  management
f substance  abuse  has  been  associated  with  commitment  to
ART treatment.28 In  fact,  substance  abuse  has  been  iden-
iﬁed as  a  relevant  public  health  problem  and  the  WHO
ecommends the  use  of  ASSIST  as  a  screening  tool  to  be
ncorporated in  primary  health  care  settings  and  in  all  con-
exts where  a  signiﬁcant  proportion  of  patients  may  be
xposed to  it,  such  as  in  sexually  transmitted  disease  clin-
cs. According  to  WHO  guidelines,  the  routine  use  of  ASSIST
ncreases the  opportunities  for  early  detection  of  drug  abuse
nd for  launching  a  discussion  about  it  with  both  patients  and
heir families.
This study  conﬁrmed  that  pharmacy  reports  are  accu-
ate predictors  of  viral  suppression.  Similar  results  have
een found  among  HIV-infected  adults  in  Africa,29 as  well
s in  Brazilian  adults,  children,  and  adolescents.12,30 Phar-
acy reports  can  provide  useful  information  that  can  be
asily incorporated  into  routine  care  as  a  monitoring  tool.
he Brazilian  AIDS  department  deﬁnes  pharmacy  visits
ith intervals  greater  than  38  days  as  indicative  of  non-
dherence, and  advises  health  units  to  utilize  mechanisms
o alert  professionals  whenever  this  happens.  The  present
esults reinforce  the  need  to  trigger  the  alert  mechanism  as
oon as  delays  occur.
The limitations  of  this  study  include  putative  biases
elated to  patient  selection  at  the  sites  (probably  compris-
ng intra-  as  well  as  inter-site  unmeasured  heterogeneities)
nd the  cross-sectional  design,  which  did  not  allow  the  eval-
ation of  adherence  over  time  and  the  proper  deﬁnition
f the  directionality  of  some  of  the  observed  associations
i.e., those  in  which  bidirectional  associations  are  plausi-
le). Unfortunately,  data  regarding  HIV  genotyping  was  not
vailable  for  all  patients,  and  thus  this  aspect  of  virological
ailure was  not  evaluated.  The  relatively  small  number  of
atients enrolled  in  some  sites  did  not  allow  for  a  statistical
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270  
nalysis  stratiﬁed  by  geographical  location  (i.e.,  the  respec-
ive ﬁve  Brazilian  macro-regions).
We  report  the  ﬁndings  from  a  Brazilian  multicenter  study
n cART  adherence  in  a  pediatric  population.  This  study’s
ndings indicate  the  usefulness  of  pharmacy  reports  along
ith the  use  of  an  integrated  package  of  standard  instru-
ents, such  as  WHOQOL-BREF  and  ASSIST,  which  should
e used  in  an  attempt  to  provide  a  more  comprehensive
pproach and  optimal  management  and  care  for  families
ith children  and  adolescents  living  with  HIV/AIDS.
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